Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases - PubMed
4 hours ago
- #inflammatory diseases
- #antifungal repurposing
- #NLRP3 inflammasome
- Ciclopirox olamine (CPX), an FDA-approved antifungal, is identified as a novel NLRP3 inflammasome inhibitor.
- CPX specifically blocks NLRP3 by binding to its NACHT domain at Y381, reducing ATPase activity and inhibiting oligomerization.
- This compound shows therapeutic effects in mouse models of sepsis, colitis, and metabolic disorders, and is active in cells from healthy individuals and gout patients.